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Abstract
Background: Obsessive-compulsive disorder (OCD) is a clinically and etiologically heterogeneous syndrome. The high 
frequency of obsessive-compulsive symptoms reported in subjects with the 22q11.2 deletion syndrome (DiGeorge/
velocardiofacial syndrome) or Prader-Willi syndrome (15q11-13 deletion of the paternally derived chromosome), 
suggests that gene dosage effects in these chromosomal regions could increase risk for OCD. Therefore, the aim of this 
study was to search for microrearrangements in these two regions in OCD patients.
Methods: We screened the 15q11-13 and 22q11.2 chromosomal regions for genomic imbalances in 236 patients with 
OCD using multiplex ligation-dependent probe amplification (MLPA).
Results: No deletions or duplications involving 15q11-13 or 22q11.2 were identified in our patients.
Conclusions: Our results suggest that deletions/duplications of chromosomes 15q11-13 and 22q11.2 are rare in OCD. 
Despite the negative findings in these two regions, the search for copy number variants in OCD using genome-wide 
array-based methods is a highly promising approach to identify genes of etiologic importance in the development of 
OCD.
Background
Obsessive-compulsive disorder (OCD) is characterized
by recurrent and intrusive thoughts and ritualistic behav-
iors or mental acts that a person feels compelled to per-
form. Although the etiology of OCD remains unknown,
the results of twin studies, familial studies, and segrega-
tion analyses have provided compelling evidence that
OCD has a strong genetic component [1]. However, OCD
fails to follow Mendelian patterns of inheritance and is
considered a complex genetic disorder. Several theoreti-
cally relevant functional candidate genes have been
examined in OCD, but no susceptibility genes have yet
been identified with certainty [1]. Like in other neuropsy-
chiatric conditions, the difficulty in identifying the
responsible genes may be the consequence of the clinical
and genetic heterogeneity of the disorder.
Chromosomal rearrangements have been reported in a
small number of individuals with OCD [2-7]. Two
microdeletion disorders, 22q11.2 deletion syndrome and
Prader-Willi syndrome (PWS), due to deletion of chro-
mosome 15q11-13, are frequently associated with obses-
sive-compulsive symptoms, suggesting that gene dosage
effects at these two loci could contribute to the develop-
ment of the obsessive-compulsive phenotype. 22q11.2
deletion syndrome, also known as DiGeorge or velocar-
diofacial syndrome, is a highly variable disorder caused
by a microdeletion of chromosome 22q11.2, often occur-
ring de novo (80%), with an estimated prevalence of 1/
2000-6000 live births [8,9]. The majority of 22q11.2 dele-
tions (87%) are ~3 Mb in size, whereas a small proportion
(8%) involves smaller nested ~1.5 Mb deletions [10] (Fig-
ure 1). 22q11 deletion syndrome is characterized by car-
diac malformations, immunodeficiency, dysmorphic
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features, and palate anomalies, associated with cognitive
impairment. Comorbid psychophathologies are fre-
quent, and include schizophrenia, attention deficit-
hyperactivity disorder, autism spectrum disorders and
OCD or obsessive-compulsive symptoms [11]. In particu-
lar, 33% (14/43) of 22q11.2 deletion subjects meet criteria
for OCD and an even higher proportion report obsessive-
compulsive symptoms (83%) [12], suggesting that the
22q11.2 locus harbors genes that could predispose to
OCD. Other researchers have also noted increased rates
of marked obsessive-compulsive symptoms and OCD
among patients with 22q11 deletion syndrome, with rates
of OCD of 8% (2/25) [13], 10.7% (3/28) [14], and 14% (2/
14) [15]. In contrast to the study by Gothelf and col-
leagues [12], the latter studies did not search systemati-
cally for OCD in their patients, which might explain the
lower frequency. The COMT gene, coding for the enzyme
catechol-O-methyltransferase, responsible for dopamine
and norepinephrine inactivation, is one of the prominent
candidate genes for susceptibility to mental disorders
located in this interval, and is considered a major candi-
date gene in OCD [16].
Figure 1 22q11.21 and 15q11-q13 regions. A. Schematic representation of chromosome 22q11.21 showing the genes in the region, the common 
recurrent deletions (red bars), and the segmental duplications that mediate the rearrangements (blue rectangles), termed low copy repeat (LCR) A to 
D. B. Schematic representation of the 15q11-q13 region deleted in Prader-Willi and Angelman syndromes. Paternally expressed genes are shown in 
yellow, maternally expressed genes in orange. Recurrent deletions are represented as red bars; the segmental duplications that mediate the rear-
rangements, termed breakpoint (BP) 1 to 3, are portrayed as blue rectangles.
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PWS is the result of the loss of expression of several
imprinted genes located in the 15q11-q13 region, which
are normally expressed on the paternally derived chro-
mosome [17] (Figure 1). In 70% of PWS patients, a pater-
nal 15q11-q13 deletion is found. The remaining have a
uniparental maternal disomy 15 (~25%) or an imprinting
defect (~5%). This neurodevelopmental disorder has an
estimated prevalence of 1/10000 live births and is charac-
terized by infantile hypotonia, neonatal feeding difficul-
ties, hypogonadism, hyperphagia (leading to obesity in
early childhood) and cognitive deficits. Many studies
have also reported a range of obsessive-compulsive and
ritualistic behaviors not related to food in about 50% of
PWS patients, including skin picking, hoarding, concerns
with symmetry, exactness, ordering and arranging, need
to tell or ask, and insistence on routines [18-21]. Thus,
paternally expressed genes within the PWS critical region
(e.g.,  MKRN3,  MAGEL2,  NDN, and SNRPN-SNURF)
could represent risk factors for OCD.
The aim of our study was to search in a sample of OCD
patients for the presence of 15q11-13 or 22q11.2 microre-
arrangements using multiplex ligation-dependent probe
amplification (MLPA). This is the first study to systemati-
cally screen these two copy number variants (CNVs) in
OCD patients. MLPA has the ability to analyze up to 50
targets in a single reaction and to detect both deletions
and duplications. The efficacy of MLPA in detecting
15q11-q13 and 22q11.2 microrearrangements has been
previously established [22,23]. We thus applied MLPA to
screen our dataset for 15q11-q13 and 22q11.2 deletions/
duplications.
Methods
Subjects
The study included 236 probands seeking treatment at
university-based OCD clinics in Paris and in Germany
(T able 1). Patients had to meet DSM-IV criteria for full
OCD [24], had to have OCD as their main disorder, and
had to be of European descent to be included in the study.
Patients with clear dysmorphic features or severe mental
retardation were excluded from the study. However, no
neuropsychological tests were performed to determine
the intellectual quotient of patients enrolled in the study.
Lifetime psychiatric evaluation was carried out during a
direct interview by trained psychiatrists using either the
French or German version of the Diagnostic Interview for
Genetic Studies (DIGS) [25] for patients over 17 years of
age, or the Kiddie Schedule for Affective Disorders and
Schizophrenia - Epidemiologic version (K-SADS-E) [26]
for probands under 17 years of age. Among the French
probands, 31% (22/71) had a history of chronic tic disor-
ders (including chronic motor or vocal tics and Tourette
syndrome), 23% (16/71) had a family history of OCD and
11% (8/71) had a family history of chronic tic disorders.
No equivalent data was available for the German sub-
jects. The local Research Ethics Boards approved the
study protocol. Written informed consent was obtained
from all participating subjects. If the proband was under
18 years old, the proband's consent and written parental
consent were obtained.
MLPA
Genomic DNA was extracted from peripheral blood leu-
kocytes or lymphoblastoid cell lines using the NucleoSpin
Blood L kit (Macherey-Nagel, Duren, Germany). MLPA
was performed using the P064 MR1 (mental retardation
1) and P250 DiGeorge kits (MRC-Holland, Amsterdam,
The Netherlands). The P064 MR1 kit detects copy num-
ber changes both at the 15q and 22q loci, and includes 5
probes specific for sequences in or near the 15q11.2
Prader-Willi syndrome/Angelman syndrome critical
region (one probe in the MKRN3, NDN, and GABRB3,
and two in UBE3A) and 6 probes in the 22q11.21
DiGeorge region (in chromosomal order: CLTCL1,
CDC45L, CLDN5, ARVCF, KLHL22, SNAP29). Informa-
tion regarding the probe sequences and ligation sites can
be obtained at http://www.mlpa.com. The P064 kit also
screens for other mental retardation syndromes: Smith-
Magenis syndrome (17p11.2), Williams syndrome
(7q11.23), 1p deletion syndrome (1p36), Sotos syndrome
(5q35.3), Miller-Dieker syndrome (17p13.3), Alagille syn-
drome (20p12.2), and Saethre-Chotzen syndrome (7p21).
Table 1: Clinical and demographic characteristics of OCD probands
French probands (n = 71) German probands (n = 165) All (n = 236)
Male/female 44/27 79/86 123/113
Age at interview (yrs) 22.2 ± 14.3 36.4 ± 12.9 31.7 ± 15.0
Age at onset of OCD (yrs) 12.7 ± 8.8 19.3 ± 10.8 17.3 ± 10.6
Y-BOCS total scorea 28.3 ± 5.4 17.2 ± 9.5 17.9 ± 9.1
a Y-BOCS, Yale-Brown Obsessive Compulsive Scale. Values are expressed as mean ± SD.Delorme et al. BMC Medical Genetics 2010, 11:100
http://www.biomedcentral.com/1471-2350/11/100
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All patients (n = 236) were screened with the P064 MLPA
kit; in addition, 126 patients were also screened with the
P250 DiGeorge kit, which contains 14 different probes in
the 22q11.2 region.
Fifty nanograms of DNA were used in the MLPA proto-
col. Experiments were performed according to the manu-
facturer's instructions but the volume of all kit reagents
was decreased by 20%. Reactions were performed on a
GeneAmp PCR System 9700 (Applied Biosystems, Foster
City, CA, USA). PCR products were analyzed by capillary
electrophoresis on an ABI Prism 3730 Genetic Analyzer
(Applied Biosystems). The resultant traces were analyzed
using the software GeneMarker 1.70 (SoftGenetics, State
College, PA, USA). After population normalization, the
peak height from each sample was compared to a syn-
thetic control, which represents the median of all normal
samples in each experiment. Peak heights below 0.75
were considered as deletions and values above 1.3 as
duplications. Cases with apparent deletions or duplica-
tions were confirmed with quantitative PCR. Apparent
deletions of a single probe were sequenced to rule out
single-base changes within the probe-binding region.
Analysis of positive controls (with confirmed 15q11-13
and 22q11.2 deletions and duplications) under the same
experimental conditions ensured the reliable detection of
copy number gains and loses.
Results
DNA from 236 unrelated individuals with OCD was
screened for 15q11-13 and 22q11.2 microrearrangements
by MLPA. No deletions or duplications were identified in
any sample in these two loci. Furthermore, no gene dos-
age abnormalities were detected in the other chromo-
somal regions screened with the MLPA P064 MR1 kit.
Discussion
Chromosomal rearrangements reported in individuals
with OCD suggest that gene dosage effects could contrib-
ute to the determinism of the disorder. To our knowledge,
this is the first study to systematically explore CNVs in
OCD. As a preliminary study, we screened a sample of
OCD patients for CNVs in the 15q11-13 and the 22q11.2
chromosomal regions. These two regions were chosen
because patients with 22q11.2 deletion syndrome or PWS
have an elevated incidence of obsessive-compulsive
symptoms [12,18,20]. We did not detect any microrear-
rangement in these regions in our sample. If present, the
prevalence of these chromosomal anomalies in OCD
would be rare, i.e. under 2 × 10-3 (<1/472 chromosomes
screened). MLPA is a highly reliable method to detect
microrearrangements in the 15q11-q13 and 22q11.2
regions, and has been used with success by our group and
others to screen subjects with autism spectrum disorders
and mental retardation [22,23,27-29]. Thus, the negative
findings in the present OCD sample cannot be ascribed
to lack of sensitivity of the method to detect copy number
abnormalities.
Despite their heterogeneity, the main clinical character-
istics of patients with PWS or 22q11.2 deletion syndrome
are relatively well recognized by psychiatrists. The non
inclusion of patients with clear dysmorphic features in
our study could explain at least in part why we were
unable to detect any subjects with such deletions. How-
ever, patients with atypical or minimal phenotype (i.e.,
patients without the congenital heart defects, palate
anomalies and distinctive facial features of the 22q11
deletion syndrome or without the characteristic obesity
of PWS), would not have been recognized by the psychia-
trists and in principle could have been included in the
OCD sample. The fact that patients with significant men-
tal retardation were absent from our sample also contrib-
utes to explain why we did not identify any subjects with
15q11-q13 or 22q11 microdeletions. Indeed, recent find-
ings have shown that pathogenic CNVs are more frequent
among individuals with moderate to severe intellectual
disability [30].
Our results also failed to identify any duplication of the
15q11-q13 or 22q11.2 regions. Maternally-derived dupli-
cations of chromosome 15q11-q13, involving the region
deleted in PWS and Angelman syndrome, confer a high
r i s k  o f  a u t i s m  s p e c t r u m  d i s o r d e r  o r  a u t i s t i c  f e a t u r e s ,
whereas paternal inheritance usually leads to a normal
phenotype or mild developmental delay [31,32]. Recent
technical progresses have lead to the identification of new
chromosomal microrearrangements, including the recip-
rocal duplications of 22q11.2 deletions [33,34]. 22q11.2
microduplications are characterized by highly variable
and subtle phenotypes. The majority of individuals have
cognitive deficits including speech delay and develop-
mental delay [33,35]. In addition, 22q11.2 microduplica-
tions can be inherited from relatives with no distinctly
recognizable phenotype, suggesting reduced penetrance
[36]. OCD or obsessive-compulsive symptoms have not
been reported in individuals with the 15q11-q13 duplica-
tion syndrome or the 22q11.2 duplication syndrome, but
given the recent identification of the latter syndrome and
the limited number of patients described [33-35,37], fur-
ther studies are needed.
Several limitations of this study should be taken into
account when interpreting its results. It is likely that there
is a selection bias in the sample of patients studied. Both
in France and in Germany, patients were recruited at
OCD outpatient clinics, where individuals with severe
developmental disabilities and associated medical condi-
tions are unlikely to come, thus decreasing the possibility
of detecting pathogenic CNVs [30]. Second, because theDelorme et al. BMC Medical Genetics 2010, 11:100
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purpose of our study was to detect the large deletions that
are typically observed in Prader-Willi and DiGeorge syn-
dromes, we did not screen for small deletions in the
15q11-q13 and 22q11 regions (none of which has been
shown to be pathogenic) or for intragenic deletions. An
additional limitation of our study is the relatively limited
size of our sample. As pathogenic CNVs are rare events,
type II errors could explain our inability to detect any
rearrangement in the 15q11-q13 and 22q11 regions.
Conclusions
In conclusion, although our study did not identify 15q11-
q13 and 22q11 microdeletions in patients with OCD, fur-
ther search of CNVs in OCD is warranted using genome-
wide approaches in large samples. The recently created
OCD International Genetics Consortium will perform
such studies with a sufficiently large number of individu-
als, by pooling DNA from different sites [1,38]. Recent
whole genome association studies and CNV analyses
using microarray technologies in other neurodevelop-
mental disorders such as autism and schizophrenia sug-
gest that CNVs are more promising to identify regions of
the genome with high probability of harboring candidate
genes, than the results of the association study itself [39-
42]. The identification of multiple, individually rare struc-
tural genomic variants throughout the genome playing a
causal role or significantly increasing the risk in neurop-
sychiatric disorders has resulted in a shift from the 'com-
mon disease-common variant' perspective to the
'multiple rare variants' perspective in the conceptualiza-
tion of these disorders. Similar advances are expected in
OCD with the use of genome-wide approaches to identify
CNVs conferring an increased risk for the disorder.
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